Astellas Pharma Inc. (ALPMY.PK), Wednesday announced new real-world preliminary data from the OPTION-VMS Phase IV study, a longitudinal, observational study in participants with VMS, also known as hot flashes and/or night sweats.
The findings demonstrated statistically significant improvements in VMS bother related to menopause, statistically significant improvements in subjective and objective sleep outcomes and significant improvements in activity impairment including overall work productivity.
Additionally, a preliminary analysis of work productivity outcomes from the study demonstrated that treating VMS associated with menopause with fezolinetant led to statistically significant improvements in Work Productivity and Activity Impairment questionnaire specific to VMS domains.
Shayna Mancuso D.O., FACOG, Head, US Medical Affairs, Women's Health-Fezolinetant, Astellas, commented, "These new preliminary findings reinforce Astellas' commitment to advancing our understanding of fezolinetant beyond the pivotal clinical trials, with the goal of driving meaningful change for those affected by VMS."
On Monday, ALPMY closed at $10.65, down 1.21 percent on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.